DPIA Advancing Biotechnology and Life Sciences Innovation

Where Science Meets Opportunity

Accelerating Growth in Biotech and Life Sciences

Dighi Port Industrial Area (DPIA) is strategically positioned to emerge as a global hub for biotechnology and life sciences. With India’s established leadership in pharmaceuticals and biopharma, DPIA offers cutting-edge infrastructure and access to international markets through its port connectivity. Whether you are pioneering biopharmaceuticals, conducting advanced R&D, or manufacturing vaccines, DPIA is your ideal partner in driving innovation and growth in life sciences.

Why DPIA for Biotechnology and Life Sciences?

India’s Biopharma Leadership

With a 20% share of the global supply of generic medicines and 60% of global vaccine production, India provides a strong foundation for biotech firms to thrive.

Strategic Location

DPIA’s proximity to Dighi Port offers seamless access to global markets for exporting high-value biopharmaceuticals, vaccines, and biologics.

R&D Collaboration

Access to leading academic institutions and research centers in Maharashtra ensures a steady pipeline of skilled talent and innovation.

Government Incentives

Benefit from supportive policies such as the Production Linked Incentive (PLI) Scheme and 100% FDI in biopharma.

Opportunities at DPIA

Biopharma Parks for Vaccine and Biologics Production

State-of-the-art facilities and plug-and-play industrial parks to enable rapid setup and scaling of manufacturing operations.

  • Facilities for manufacturing biologics, biosimilars, and advanced therapies.
  • Cold chain infrastructure for safe storage and transportation of sensitive products.
  • Export-focused production with proximity to Dighi Port.

Research and Development Hubs for New Therapies and Regenerative Medicine

DPIA provides a conducive environment for R&D in cutting-edge areas like gene therapies and regenerative medicine.

  • Incubation centers for biotech startups
  • Collaboration with academic institutions for clinical trials and translational research.
  • Innovation labs equipped with advanced technologies for biotech R&D.

Collaboration with Academic Institutions for Skill Development and Innovation

DPIA promotes partnerships with academic institutions to develop a skilled workforce and drive innovation in life sciences.

  • Industry-academia tie-ups for biotechnology and pharmaceutical education.
  • Training programs focused on advanced manufacturing techniques and R&D methodologies.
  • Establishment of Centers of Excellence in biotechnology.

Growth Drivers

India’s Biopharma Market Leadership

India is the third-largest pharmaceutical manufacturer globally and a leader in biopharma production.

Rising Global Demand for Biopharmaceuticals

Growing demand for vaccines, biosimilars, and gene therapies creates vast opportunities for expansion.

Strategic Export Potential

DPIA’s connectivity to international markets positions it as a prime location for exporting high-value biotech products.

Supportive Ecosystem

The Indian government’s focus on innovation through schemes like the PLI and National Biopharma Mission fosters growth in the sector.

What Makes DPIA Unique?

Integrated Biotech Infrastructure

DPIA offers plug-and-play facilities for biotech manufacturing, R&D, and clinical trials.

Seamless Global Connectivity

Proximity to Dighi Port ensures cost-effective logistics for exporting biopharmaceuticals to key markets.

Skilled Talent Pool

Collaboration with local universities and research institutes ensures access to trained professionals in biotechnology and life sciences.

Sustainability Focus

DPIA’s commitment to sustainability aligns with global ESG standards, attracting impact-driven biotech investors.

Government Initiatives Supporting Biotechnology

  • Production Linked Incentive (PLI) Scheme:
    Financial incentives to boost domestic manufacturing of biopharmaceuticals, APIs, and advanced therapies.
  • National Biopharma Mission:
    Aims to accelerate the development of biopharmaceuticals through innovation and capacity building.
  • 100% FDI:
    Automatic route for FDI in biopharma and life sciences to attract global players.
  • Clinical Trial Reforms:
    Simplified regulations and faster approvals for clinical trials to encourage R&D investments.

Invest in Biotechnology and Life Sciences at DPIA

With world-class infrastructure, a strategic location, and access to a thriving biopharma ecosystem, DPIA is your gateway to success in biotechnology and life sciences. Join us in advancing innovation and creating a healthier future.

Dighi is the Bridge Between
the Global North and the Global South.

About

The is a Public Benefit Corporation (PBC) with a mission to establish Dighi as a key player in international economic collaboration, focusing on strategic partnerships with nations like USA, Europe, Australia, African Union, KSA, China, India, Qatar, Saudi Arabia, Türkiye, and the UAE across vital sectors such as energy, technology, agriculture, and finance. Our goal is to integrate lessons from successful global economic models, adopting best practices to ensure sustainable and inclusive growth. We aim to enhance economic prosperity and diversification, contribute to societal progress, and promote sustainable economic practices. By leveraging Dighi’s unique position, strives to drive substantial economic growth, spur innovation, and solidify Dighi’s stature in the international economic arena, resonating with the government’s vision of a technologically advanced and interconnected economy.

Contact

Newsletter

Please enable JavaScript in your browser to complete this form.

Copyright © 2025 All Rights Reserved. Dighi Port Industrial Area (DPIA) powered by WSSH Australia